Analysis: Thomas H. Kean Jr's sale of JNJ (Johnson & Johnson)
Assessment: On watch
A high-jurisdiction-fit sale that appears to be part of a routine exit from healthcare rather than an informed trade, given the missed post-earnings rally.
- Member: Thomas H. Kean Jr
- Party / state: Republican, NJ-7
- Chamber: Representatives
- Transaction: Sale
- Amount: $15,001 - $50,000
- Ticker: JNJ
- Company: Johnson & Johnson
- Trade date: 2026-01-23
- Disclosure date: 2026-02-19
- Disclosure lag: 27 days
Executive summary
Rep. Thomas H. Kean Jr, a member of the House Energy and Commerce Committee (Health Subcommittee), sold $15,001 - $50,000 of Johnson & Johnson (JNJ) on January 23, 2026. This sale occurred nine days after a subcommittee hearing on healthcare innovation and eight days prior to JNJ's Q4 earnings announcement. The trade aligns with a broader pattern of Kean Jr liquidating healthcare positions, including Stryker (SYK).
The trade is part of a systematic divestment; Kean Jr sold JNJ in July 2025, November 2025, and January 2026, alongside seven sales of SYK. Notably, the January 23 sale took place between a relevant Health Subcommittee hearing (Jan 14) and the company's earnings call (Jan 31). While JNJ reported an earnings beat, the stock price at the time of sale ($220.14) was significantly lower than the price shortly after disclosure ($242.49), suggesting the member did not capture the subsequent rally. The member's committee role provides direct oversight of the FDA and pharmaceutical policy, which are primary risk factors for JNJ. However, the consistent selling pattern suggests a portfolio-wide exit from the sector rather than a reactionary trade based on specific non-public catalysts.
Timeline
- 2025-11-20 — Kean Jr sells JNJ ($15k-$50k)
- 2026-01-14 — House Health Subcommittee hearing on healthcare innovation
- 2026-01-23 — Kean Jr sells JNJ ($15k-$50k) - CURRENT TRADE
- 2026-01-31 — JNJ Q4 Earnings Report
- 2026-02-17 — JNJ EVP Vanessa Broadhurst sells $1.5M in stock
- 2026-02-19 — Kean Jr files disclosure for Jan 23 trade
Independent analysis of public financial disclosures. Not financial or investment advice.
Sources
- Johnson & Johnson (NYSE:JNJ) EVP Sells $1,508,287.83 in Stock - Ticker Report
- Congressional Trading Report: Rep. Thomas Kean Sold Over $31K In Johnson & Johnson Stock - Check Point Software (NASDAQ:CHKP), Johnson & Johnson (NYSE:JNJ) - Benzinga
- Congress Trade: Representative Thomas H. Kean, Jr. Just Disclosed New Stock Trades
- Which stocks is Thomas Kean Jr trading
- Johnson & Johnson Stock (JNJ) Opinions on Recent 52-Week High | Quiver Quantitative
- All reports
- Financials - SEC filings | Johnson & Johnson
- Form 10-K 2024 122924
- Form 10-K 2024 122924